Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px
Document › Details

Albireo AB. (4/3/12). "Press Release: Ajinomoto Pharmaceuticals and Albireo Announce Japan and Asia License Agreement for Elobixbat". Tokyo & Gothenburg.

Region Region Japan
Organisations Organisation Albireo AB
  Organisation 2 Ajinomoto Pharmaceuticals Co., Ltd.
  Group Ajinomoto (Group)
Products Product elobixibat (A3309)
  Product 2 gastrointestinal drug
Index term Index term Ajinomoto–Albireo: elobixibat, 201204– license excl for developm + commercialisation in Japan + Korea + Thailand + Indonesia + Vietnam + Taiwan
Persons Person Chiswell, David (Kymab 201604–201904 CEO before interim CEO since early 2015 before Nabriva + Albireo + CAT + Amersham)
  Person 2 Toyoda, Tomoyasu (Ajinomoto 201204 CEO of Ajinomoto Pharmaceuticals Co Ltd)
     


   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Albireo AB


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px




» top